Dimension Vista 500, model no. 10284473 an in vitro diagnostic device intended to duplicate manual analytical procedures such as pipetting, mixing, heating, and measuring spectral intensities to determine a variety of analytes in human body fluids.
Publicado el 26 de diciembre de 2018 · Inicio del retiro: 16 de octubre de 2018
Resumen
FDA registra el retiro Z-0616-2019 de dispositivos médicos de Clase II, publicado el 26 de diciembre de 2018 e iniciado el 16 de octubre de 2018. Empresa responsable: Siemens Healthcare Diagnostics, Inc.; Estado: Finalizado; Cantidad reportada: 1649; Lote: Dimension Vista software versions 3.7 and 3.8.1. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Siemens Healthcare Diagnostics has identified an issue with Dimension Vista software v.3.7 and v.3.8.1 that may result in aliquot well contamination. If a test is cancelled by the operator while the instrument is aliquotting the sample, the Dimension Vista instrument may continue to deliver the cancelled sample or vial contents to the aliquot well(s). Future samples may be assigned to the same aliquot well(s) and become contaminated with the existing contents or overflow of the aliquot well may occur potentially contaminating a surrounding well(s). This issue only occurs when an operator manually cancels a test(s) for calibration, quality control (QC) or patient sample while the instrument is in the process of aliquotting the sample.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Siemens Healthcare Diagnostics, Inc.
- Distribuidor
- Nationwide/worldwide distribution.
- Lote
- Dimension Vista software versions 3.7 and 3.8.1
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAAtellica CH Revised C-Reactive Protein (RCRP); Siemens Material Number (SMN): 11537223;7 de octubre de 2026
- FDABeckman Coulter, Emit 2000 Quinidine Assay REF: OSR4Q229 Contents: R1: 2 x 23 mL;R2 2x13 mL26 de agosto de 2026
- FDASyva EMIT 2000 Quinidine Assay REF: 4Q019UL Contents: 1x28 mL, 1x14mL26 de agosto de 2026
- FDASyva Emit tox Serum Tricyclic Antidepressant Calibrator/Controls SMN 10445390 Catalog No. 7C219UL12 de agosto de 2026
- FDAInspired Organic Peanut Butter 16oz. plastic jar, 6 per case UPC #: 863669742588 refrigerate after opening26 de diciembre de 2018
- FDAultra2 Genesys Variants Analyzer, REF 03-01-0045 intended to be used with automated high performance liquid26 de diciembre de 2018
Preguntas sobre este retiro
¿Dimension Vista 500, model no. 10284473 an in vitro diagnostic device intended to duplicate manual analytical procedures such as pipetting, mixing, heating, and measuring spectral intensities to determine a variety of analytes in human body fluids. fue retirado del mercado?
Sí. FDA publicó el retiro Z-0616-2019 el 26 de diciembre de 2018. Peligro reportado: Siemens Healthcare Diagnostics has identified an issue with Dimension Vista software v.3.7 and v.3.8.1 that may result in aliquot well contamination. If a test is cancelled by the operator while the instrument is aliquotting the sample, the Dimension Vista instrument may continue to deliver the cancelled sample or vial contents to the aliquot well(s). Future samples may be assigned to the same aliquot well(s) and become contaminated with the existing contents or overflow of the aliquot well may occur potentially contaminating a surrounding well(s). This issue only occurs when an operator manually cancels a test(s) for calibration, quality control (QC) or patient sample while the instrument is in the process of aliquotting the sample.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter